TABLE 1

Hemodynamic and echocardiographic characteristics of type 1 diabetic patients and healthy control subjects in basal state and during dipyridamole stress before and during C-peptide infusion

Patients (before)
Patients (C-peptide)
Control subjects
BasalP*DipyridamoleBasalPDipyridamoleBasalDipyridamole
Hemodynamics
 Heart rate (bpm)54 ± 2NS79 ± 358 ± 3NS80 ± 361 ± 380 ± 5
 Blood pressure systole (mmHg)115 ± 3NS121 ± 5112 ± 5NS117 ± 5118 ± 5107 ± 3
 Blood pressure diastole (mmHg)68 ± 4NS66 ± 462 ± 4NS62 ± 471 ± 260 ± 4
 Rate pressure product (mmhg/min)6,193 ± 109NS9,626 ± 6096,438 ± 412NS9,443 ± 6417,233 ± 5228,689 ± 650
Tissue Doppler velocities
 Systole (cm/s)80 ± 30.069.9 ± 0.48.9 ± 0.5<0.069.8 ± 0.58.8 ± 0.210.0 ± 0.3§
 Early diastole (cm/s)13.8 ± 0.6<0.0415.5 ± 0.515.4 ± 0.6<0.0416.3 ± 0.7§15.6 ± 0.517.3 ± 0.4
 Atrial contraction (cm/s)7.0 ± 0.7NS9.0 ± 0.57.2 ± 0.6NS8.9 ± 0.6§7.8 ± 0.48.8 ± 0.6
Perfusion
 SImax (a.u.)6.6 ± 0.6<0.0411.4 ± 1.58.1 ± 0.7<0.0211.5 ± 0.8§8.2 ± 0.610.5 ± 0.4
 MBVI (%)23 ± 2<0.0538 ± 328 ± 2NS42 ± 4§29 ± 243 ± 4
 β0.52 ± 0.06NS0.74 ± 0.20.67 ± 0.11NS0.81 ± 0.200.55 ± 0.060.68 ± 0.09
 MBFI (SImax × β)3.3 ± 0.4<0.076.2 ± 1.25.3 ± 0.9<0.059.7 ± 2.44.5 ± 0.45.6 ± 0.2§
  • Data are means ± SEM.

  • *

    * P values between the patients’ basal values before C-peptide infusion and the control subjects’ basal values;

  • P values between patients’ basal values before and during C-peptide infusion;

  • P < 0.05,

  • §

    § P < 0.01,

  • P < 0.001 between dipyridamole stress values versus corresponding basal values. β, rate constant as measure of flow rate.